Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965186 | 0.90 | CYP19A1 (0.43) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9965131 | 0.87 | CYP19A1 (0.41) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1242629 | 0.85 | CYP19A1 (0.57) | CYP19A1CYP17A1KCNA5TSHR | |
| SCHEMBL1243320 | 0.84 | CYP19A1 (0.44) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1242145 | 0.83 | CYP19A1 (0.45) | CYP19A1CYP17A1KCNA5ALDH1A1 | |
| SCHEMBL1242375 | 0.81 | CFTR (0.41) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9965132 | 0.77 | KCNA5 (0.40) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27684288 | 0.75 | CYP19A1 (0.46) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1242323 | 0.74 | CYP19A1 (0.39) | CYP19A1KDM4EKCNA5ALDH1A1TSHR | |
| SCHEMBL5547149 | 0.73 | CYP19A1 (0.44) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2012082746-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| EP-1781635-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | CYP19A1 4632/4885CFTR 256/4885SLC6A2 382/4885 |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP19A1 898/4885CFTR 183/4885SLC6A2 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.